New York University

Genentech, Inc.

Chiron Corporation

Victor N Nussenzweig

Ruth S Nussenzweig

David W Martin, Jr

Ingrid W Caras

Michael A Davitz

Philip J Barr

Andres Ruiz

Vincenzo Enea

Arturo Ferreira

Fidel Zavala

David E Arnot

Ulises Vergara

G Nigel Godson

Pamela S Svec

Joan Ellis

David H Schlesinger

Pedro Potocnjak

Arturo Ferreira Vigouroux

David R Colman

Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.

Decay accelerating factor (DAF) and nucleic acid encoding it

This application relates to nucleic acids encoding decay accelerating factor (hereinafter abbreviated as DAF), as well as vectors and cells which comprise such nucleic acids. Additionally, nucleic acids which encode variants of DAF, such as insertion, deletion or substitution variants, are described. This application also relates to the preparation of DAF in recombinant cell culture. In particular, it is concerned with the large scale manufacture of DAF suitable for pharmaceutical or diagnostic use.

Decay accelerating factor (DAF) and nucleic acids encoding it

Immunogenic peptide antigen corresponding to plasmodium vivax

Described is a antigen and antigenic amino acid sequence consisting of repeating units of the immunodominant epitope region of the circumsporozoite surface protein of a parasite of the genus Plasmodium. Also described is a related fusion protein produced by a recombinant microorganism and a vaccine for immunizing mammals against malaria.

Protective peptide antigen

Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.

Nucleic acids vectors and cells for the synthesis of membrane anchor

The present invention provides an immunoassay of general applicability. The assay detects an antigen by its inhibition of the reaction between the combining site of two antibodies. One of the antibodies binds antigen, and the second antibody binds to the combining site or idiotype of the first antibody. It is preferable that both the antibody that binds the antigen and the anti-idiotypic antibody are monoclonal antibodies. The assay provides a method for measuring concentrations of single epitopes without requiring purified antigen, and it is particularly useful for measuring the quantity of any nonpurified antigen present in low concentration in a mixture of antigens. The use of monoclonal antibodies as reagents is advantageous in providing an essentially unlimited supply of highly specific and standardized reagents, without the batch-to-batch variation encountered when using conventional polyclonal antibodies. The invention further provides a screening method for isolating the appropriate monoclonal antibodies of anti-idiotypic specificity.

Idiotype-anti-idiotype immunoassay

Disclosed is a peptide antigen comprising an amino acid sequence of a non-repetitive epitope of the circumsporozoite protein of a sporozoite of the genus plasmodium said peptide having the property of eliciting formation of antibodies that bind to said nonrepetitive epitope on the sporozoite surface said peptide being synthetic, purified and substantially shorter in length than said protein.

Cross-reactive and protective epitopes of circumsporozoite proteins

This invention relates to a synthetic polypeptide (preferably produced by recombinant DNA techniques) comprising an amino acid sequence incorporating (a) a portion of the P.vivax circumsporozoite (CS) protein including the region of the repeat immunodominant epitope of said protein and (b) another portion of such protein which is conserved among the different material species; and to a method for purifying such a polypeptide.

Immunogenic polypeptide and method for purifying it

Membrane anchor fusion polypeptides

Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.

Vaccine against the sporozoite stage of malaria

Disclosed are peptides comprising the amino acids

Immunogenic peptide corresponding to P. vivax CS protein

Synthetic peptides containing non-repeating epitopes of circumsporozoite derived protein antigen and which are substantially shorter in length than the intact antigen are disclosed. The peptides when administered to a host raise antibodies in that host that will bind to the circumsporozoite antigen on the parasite. Vaccines based upon these peptides, as well as means of raising antibodies to circumsporozoite antigens using the synthetic peptides are also disclosed.

Cross-reactive and protective epitopes of CS

A method for inhibiting the development or limiting the extent of malarial parasitemia in mammals comprising administering an amount of gamma-interferon sufficient to inhibit parasitemia, said parasitemia being incident to invasion of said mammal by sporozoites of a member of the genus Plasmodium. The administration of gamma-interferon takes place no later than the end of the prepatency period of said mammal (or of the dormant phase of the parasite as the case may be).

Method for preventing the development or decreasing the extent of

Immunogenic recombinant yeast expression product and method for

Disclosed are peptides the sequence of which defines an immunodominant epitope from the repetitive immunodominant epitope region of the circumsporozoite (CS) protein of a member of the genus Plasmodium, the sequence of the peptide being shorter in length than the repeating unit of the CS protein.

Growing community of inventors

New York, NY, United States of America

Victor N Nussenzweig